US 6,855,823 B2 · Selective iGluR5 receptor antagonists

Abstract

The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.

Claims1

Dependent claims

A compound which is 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-2-methoxycarbonyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate.

Dependencies are inferred from the claim text.

Facts

Application

10/821,698Filed 9 Apr 2004 · continuation

Priority

6 Jul 1999

Published

US 2004/0192722 A130 Sep 2004

Granted

15 Feb 2005

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

C07D 401/06
Containing two hetero rings: linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/472
Quinolines; Isoquinolines: non-condensed isoquinolines, e.g. papaverine
A61K 31/4725
Non-condensed isoquinolines, e.g. papaverine: containing further heterocyclic rings

Family

Application60/142,485Us provisional application · filed 6 Jul 1999

Application60/151,165Us provisional application · filed 27 Aug 1999

PCTUS00/16297Parent of this continuation · filed 27 Jun 2000

Application10/383,296Parent of this continuation · filed 6 Mar 2003

US 2004/0192722 A1Pre-grant publication · published 30 Sep 2004

US 6,759,418 B2Parent of this continuation

Application10/009,655Parent of this continuation

US 6,566,370 B1Parent of this continuation

US 2003/0199546 A1Published application

US 6,855,823 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

10/821,698Filed 9 Apr 2004 · continuation

Priority

6 Jul 1999

Published

US 2004/0192722 A130 Sep 2004

Granted

15 Feb 2005

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

C07D 401/06
Containing two hetero rings: linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/472
Quinolines; Isoquinolines: non-condensed isoquinolines, e.g. papaverine
A61K 31/4725
Non-condensed isoquinolines, e.g. papaverine: containing further heterocyclic rings

Family

Application60/142,485Us provisional application · filed 6 Jul 1999

Application60/151,165Us provisional application · filed 27 Aug 1999

PCTUS00/16297Parent of this continuation · filed 27 Jun 2000

Application10/383,296Parent of this continuation · filed 6 Mar 2003

US 2004/0192722 A1Pre-grant publication · published 30 Sep 2004

US 6,759,418 B2Parent of this continuation

Application10/009,655Parent of this continuation

US 6,566,370 B1Parent of this continuation

US 2003/0199546 A1Published application

US 6,855,823 B2This patent

From the US filing history. Foreign family members aren’t listed.

Selective iGluR5 receptor antagonists

Life of this patent

Abstract

Claims1

Selective iGluR5 receptor antagonists

Life of this patent

Abstract

Claims1